Imipenem + Cilastatina Venus Pharma

Imipenem/cilastatin, the active ingredient in Imipenem + Cilastatina Venus Pharma, is a carbapenem antibiotic presented as an injection for intravenous use. It treats serious bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, complicated skin and soft tissue infections, febrile neutropenia, and nosocomial pneumonia in hospitalized patients.

GNH USA supplies Imipenem + Cilastatina Venus Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/cilastatin is used for a range of serious bacterial infections that require intravenous therapy.

- Complicated intra‑abdominal infections: provides broad‑spectrum bacterial coverage to resolve infection. - Complicated urinary tract infections: eliminates resistant uropathogens and restores urinary sterility. - Complicated skin and soft tissue infections: eradicates mixed Gram‑positive and Gram‑negative organisms. - Febrile neutropenia: offers rapid bactericidal activity in immunocompromised patients. - Nosocomial pneumonia: treats hospital‑acquired lung infections caused by multidrug‑resistant bacteria.

Adverse reactions may occur with imipenem/cilastatin therapy and are categorized by frequency.

Common Side Effects: - Nausea - Diarrhea - Headache - Rash - Elevated liver enzymes - Injection‑site phlebitis

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (anaphylaxis) - Clostridioides difficile‑associated colitis - Renal impairment - Thrombocytopenia - Neutropenia

When prescribing imipenem/cilastatin, clinicians should consider several safety aspects.

- Renal function: adjust dose in patients with impaired renal clearance. - Seizure risk: monitor patients with a history of CNS disorders or receiving concomitant neurotoxic drugs. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactam antibiotics. - Drug interactions: review concomitant medications that may lower seizure threshold or affect renal excretion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin may interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Valproic acid: co‑administration reduces valproate levels, risking loss of seizure control. - Other carbapenems: concurrent use may increase neurotoxicity and renal burden.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance nephrotoxic potential. - Aminoglycosides: combined use can increase risk of renal impairment. - NSAIDs: may further compromise renal function. - Warfarin: imipenem can alter INR, requiring closer monitoring. - Oral contraceptives: efficacy may be reduced, advise additional contraceptive measures.